Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016

Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016

Abstract Background Direct-acting anti-viral agents have improved the treatment of chronic hepatitis C virus (HCV) infection, but this treatment is challenging for patients using co-medications because of potential drug–drug interactions. This study aimed to examine the comorbidities and co-medicati...

Full description

Bibliographic Details
Main Authors: Daniel J. Ruzicka, Jumpei Tetsuka, Go Fujimoto, Tatsuya Kanto
Format: Article
Language:English
Published: BMC 2018-05-01
Series:BMC Infectious Diseases
Subjects:
Chronic hepatitis C
Comorbidity
Drug interactions
Japan
Polypharmacy
Online Access:http://link.springer.com/article/10.1186/s12879-018-3148-z

Internet

http://link.springer.com/article/10.1186/s12879-018-3148-z

Similar Items